Clinical Trials
44 trialsBC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
Case Comprehensive Cancer Center
PRISM
Weill Medical College of Cornell University
A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants
Rutgers, The State University of New Jersey
Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases
University of Texas Southwestern Medical Center
Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
University of Colorado, Denver
ESR-22-21719
Georgetown University
BOUNCE
ETOP IBCSG Partners Foundation
Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab
Indiana University
SCION
University of British Columbia
LURBIMUNE
Institut Bergonié
Chemo-free BRCA-targeted Neoadjuvant Strategy
European Organisation for Research and Treatment of Cancer - EORTC
A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations
M.D. Anderson Cancer Center
Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial
University of Washington
Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment
Columbia University
MATILDA
Gustave Roussy, Cancer Campus, Grand Paris
Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)
AIO-Studien-gGmbH
Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients
Hoosier Cancer Research Network
SOLUTION
European Organisation for Research and Treatment of Cancer - EORTC
Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma
Yale University
Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer
Emory University
PANDoRA
Cedars-Sinai Medical Center
ADHERE
European Organisation for Research and Treatment of Cancer - EORTC
DOMINATION
University Health Network, Toronto
DOME
University Health Network, Toronto
Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer
University of California, San Francisco
Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC
MedImmune LLC
A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection
University of Colorado, Denver
PIVOT-RCC
Washington University School of Medicine
Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer
Stony Brook University
TRIO Bladder
Duke University
CEDUVEAL-M
Grupo Español Multidisciplinar de Melanoma
Panc-Durval+RT
University of Maryland, Baltimore
Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
Northwestern University
Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer
Iovance Biotherapeutics, Inc.
Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer
NYU Langone Health
IDA-D
Insel Gruppe AG, University Hospital Bern
MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma
University of Michigan Rogel Cancer Center
Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
University of Washington
PRIMED-001
University Health Network, Toronto
Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC
Columbia University
Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer
University of California, San Francisco
Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer
Peregrine Pharmaceuticals